INmune Bio, Inc. (INMB)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of INmune Bio, Inc. (“INmune” or the “Company”) (NASDAQ: INMB). Investors who purchased INmune securities are encouraged to obtain additional information and assist the investigation.


The investigation concerns whether INmune and certain of its officers and/or directors have violated federal securities laws.

On May 23, 2022, INmune issued a press release “announc[ing] that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™).  As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold.  The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days.”  On this news, INmune’s stock price fell $1.79 per share, or 24.62%, to close at $5.48 per share on May 24, 2022.


If you are aware of any facts relating to this investigation or purchased INmune shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 


Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.